Should I Buy LTH? LTH 2026 Analysis

Should You Buy Life Time Group Holdings Inc (LTH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

29.820

1 Day change

3.69%

52 Week Range

34.990

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: trend is broadly bullish, but momentum is cooling and near-term data (options + pattern stats + hedge fund selling) argues for chop/down first.
Upside is attractive vs Street targets (roughly $37–$43 vs $28.99), but timing is unfavorable with earnings (Feb 24 pre-market) approaching and no proprietary buy signal today.
If you must act immediately: prefer waiting for either (1) a pullback toward support ~$28.17–$27.49, or (2) a reclaim/close above ~$30.37 (R1) to reduce near-term downside risk.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Primary trend: bullish with stacked moving averages (SMA_5 > SMA_20 > SMA_200), implying an established uptrend.
Momentum: weakening as MACD histogram is positive (0.105) but contracting, suggesting upside pressure is fading short-term.
RSI(6)=~59.9 (neutral-to-slightly-bullish): not overbought, but also not a clear “oversold dip buy.”
Key levels: Pivot 29.268 (price 28.99 is slightly below pivot = mild near-term weakness). Support S1 28.17 then S2 27.492. Resistance R1 30.365 then R2 31.043.
Context: down -2.12% on a risk-off day (S&P 500 -1.29%), but LTH still needs to defend ~28.17 to keep the short-term structure clean.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Open interest put/call = 0.89: positioning slightly favors calls (not bearish structurally).
Volume put/call = 1.55: today’s flow is more put-heavy, implying near-term caution/hedging.
Implied vol (30d) 42.82 vs historical vol 32.12: options are pricing elevated forward uncertainty (consistent with earnings in ~3 weeks).
Volume is very light vs recent averages (today volume 28 vs 5d/10d averages 176.8/221.9), so sentiment signal is directionally bearish but not high-conviction.
IV rank 8.58 / IV percentile 46.61: IV is not extreme vs its own history; not screaming panic, but not “cheap vol” either.

Technical Summary

Sell

Buy

Positive Catalysts

- Strong growth backdrop (latest reported quarter 2025/Q3) with double-digit revenue growth and sharply higher profitability.
- Earnings catalyst ahead: Q4 and full-year 2025 results scheduled for Feb 24 (pre-market); can re-rate shares if guidance surprises positively.
- Analyst stance remains constructive (multiple Buy/Outperform/Overweight ratings; targets far above current price).
- Company initiatives/news flow (heart health programs) supports brand positioning and member engagement narrative.

Neutral/Negative Catalysts

- Hedge funds are selling (selling amount up ~163.86% over the last quarter), a notable near-term headwind.
- Near-term options tape is cautious (put volume > call volume), consistent with short-term downside/hedging.
- Pattern-based forecast skews slightly negative: estimated -2.07% next week and -2.16% next month.
- Event risk into earnings (Feb 24): with no proprietary buy signal today, the setup is less attractive for an impatient entry.

Financial Performance

Latest quarter: 2025/Q3
Revenue: $782.649M, +12.90% YoY (solid top-line growth).
Net income: $102.427M, +147.68% YoY (strong operating leverage/profit inflection).
EPS: $0.45, +136.84% YoY (meaningful earnings acceleration).
Gross margin: 37.47%, +2.83% YoY (margin expansion supports higher quality growth trend).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Trend: Ratings stay bullish, but price targets have been modestly trimmed/adjusted at times (e.g., BofA $45→$43; Morgan Stanley $39→$37) while still maintaining positive ratings.
Most recent: BofA reiterates Buy with $43 PT (cut from $45) citing multiple trim/valuation roll-forward.
Northland reiterates Outperform with $42 PT and calls LTH a Top Pick for 2026 after solid prelim Q4 and FY26 guidance.
Morgan Stanley keeps Overweight with $37 PT (lowered from $39).
Wall Street pros: durable wellness demand tailwinds; continued execution/outperformance; strong profit growth and margin expansion.
Wall Street cons: valuation sensitivity/multiple trimming; earnings-event timing risk; near-term institutional flow (hedge fund selling) not supportive.

8 Analyst Rating

Wall Street analysts forecast LTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LTH is 40.5 USD with a low forecast of 36 USD and a high forecast of 48 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 28.760

Low

Averages

40.5

High

Current: 28.760

Low

Averages

40.5

High

BofA

Buy

downgrade

$45 -> $43

AI Analysis

2026-02-04

New

Reason

BofA

Price Target

$45 -> $43

AI Analysis

2026-02-04

New

downgrade

Buy

Reason

BofA lowered the firm's price target on Life Time Group (LTH) to $43 from $45 and keeps a Buy rating on the shares. Gen Z and Millennials are increasingly prioritizing healthy ways of living and both Planet Fitness (PLNT) and Life Time offer exposure to these trends, but at different ends of the value spectrum, the analyst tells investors. The firm cites trimming its multiple and rolling forward valuation to its 2027 EBITDA estimate for its lowered target.

Northland

Owen Rickert

Outperform

maintain

$41 -> $42

2026-01-23

Reason

Northland

Owen Rickert

Price Target

$41 -> $42

2026-01-23

maintain

Outperform

Reason

Northland analyst Owen Rickert raised the firm's price target on Life Time Group to $42 from $41 and keeps an Outperform rating on the shares after the company reported "solid" preliminary Q4 results and released its FY26 guidance. Life Time "continues to outperform our expectations," says the analyst, who adds that these results "further solidify our conviction for making LTH a Top Pick for 2026."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LTH

Unlock Now

LTH Should I Buy

LTH Should I Buy

Should You Buy Life Time Group Holdings Inc (LTH) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch